USA may face shortage of Pfizer vaccine

USA may face shortage of Pfizer vaccine

Pharmaceutical company Pfizer has warned the United States administration that it is impossible to produce enough COVID-19 vaccine for delivery. All because other countries have bought up most of the stock, the National News Service reports.

In addition, insufficient quantities could have a negative impact on the vaccine schedule in the United States.

Another problem with the supply of Pfizer vaccine is due to difficulties with logistics. For example, the storage temperature of a drug must be -70 degrees Celsius.

Recall that in summer the U.S. administration signed a contract with Pfizer and the German company BioNTech to purchase 600 million doses of vaccine worth $195 billion.

Earlier it became known that the first western country where vaccination against coronavirus started was Great Britain.